Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dynavox Group ABFRA:H3Q -1.63%82 3-Year ROIIC % is 15.35 as of Dec. 2025, which is 93% above its 10-year median of 7.94. GuruFocus rates FRA:H3Q with a GF Score™ of 82/100 and a GF Value™ of €7.92 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Dynavox Group AB ranks better than 65.99% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Dynavox Group AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 15.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Dynavox Group AB's 3-Year ROIIC % or its related term are showing as below:
FRA:H3Q's 3-Year ROIIC % is ranked better than 65.99% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 1.52
vs FRA:H3Q: 15.35
Dynavox Group AB (FRA:H3Q) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Dynavox Group AB 3-Year ROIIC % Related Terms
Dynavox Group AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Dynavox Group AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:H3Q vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Dynavox Group AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavox Group AB 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dynavox Group AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Dynavox Group AB's 3-Year ROIIC % falls into.
Dynavox Group AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 20.0520391 (Dec. 2025) - 6.288845 (Dec. 2022) )
/
( 197.513 (Dec. 2025) - 107.171 (Dec. 2022) )
=
13.7631941
/
90.342
=
15.23%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Dynavox Group AB (FRA:H3Q) has a 3-Year ROIIC % of 15.35 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Dynavox Group AB and its competitors. This is 93% above median its historical median of 7.94. According to the industry distribution chart, Dynavox Group AB ranks #270 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 34%.
Is Dynavox Group AB's 3-Year ROIIC % too high?
Dynavox Group AB's current 3-Year ROIIC % of 15.35 is 93% above median its 10-year median of 7.94. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.52. Dynavox Group AB's value of 15.35 is 909.9% above this industry median. Based on the distribution chart, Dynavox Group AB ranks #270 out of 794 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Dynavox Group AB has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dynavox Group AB's 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Dynavox Group AB ranks #270 out of 794 companies for 3-Year ROIIC %. This puts Dynavox Group AB in the upper half of its industry. The industry median 3-Year ROIIC % is 1.52. Dynavox Group AB's value of 15.35 is 909.9% above this benchmark. While the company's 10-year median is 7.94 vs. the industry median of 1.52, Dynavox Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.52, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dynavox Group AB's current 3-Year ROIIC % of 15.35 is 909.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Dynavox Group AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dynavox Group AB's current 3-Year ROIIC % is 15.35, which is 93% above median its own 10-year median of 7.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynavox Group AB stock overvalued right now?
Based on GuruFocus' analysis, Dynavox Group AB (FRA:H3Q) is currently considered Modestly Undervalued. The stock's GF Value™ is €7.92, compared to a current price of €6.64 — trading 16.2% below its estimated fair value. The current 3-Year ROIIC % is 15.35, which is 93% above median its 10-year median of 7.94 and 909.9% above the Medical Devices & Instruments industry median of 1.52. Dynavox Group AB's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Dynavox Group AB (FRA:H3Q), the current 3-Year ROIIC % is 15.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dynavox Group AB (FRA:H3Q) Overvalued in 2026?
Based on GuruFocus' analysis, Dynavox Group AB stock appears to be undervalued.
The current stock price of €6.64 is trading 16.2% below its estimated GF Value™ of €7.92.
GuruFocus considers Dynavox Group AB to be Modestly Undervalued.
Key valuation signals for FRA:H3Q:
3-Year ROIIC %: 15.35 (93% above median its 10-year median of 7.94)
GF Value™: €7.92 vs. price of €6.64 (16.2% below fair value)
Industry Position: 909.9% above the Medical Devices & Instruments median (#270 of 794)
No single metric tells the full story. See the FRA:H3Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dynavox Group AB is engaged in assistive technology for communication. The company's Augmentative and Alternative Communication (AAC) solutions enable people with disabilities such as cerebral palsy, ALS, and spinal cord injury to communicate with a voice of their own, develop literacy skills, and live more independently. The company is a comprehensive SaaS provider with local roots. The company operates in Europe, North America, and Other countries, with the majority of revenue from North America.
82GF Score
Get the complete analysis for FRA:H3Q
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3Q has been successfully added to your 
